| Symbol | OVID |
|---|---|
| Name | OVID THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1460 BROADWAY,SUITE 15021, NEW YORK, New York, 10036, United States |
| Telephone | +1 646 661-7661 |
| Fax | — |
| — | |
| Website | https://www.ovidrx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001636651 |
| Description | Ovid Therapeutics Inc is a biopharmaceutical company. The firm is primarily engaged in developing impactful medicines for patients and families living who are suffering from epilepsies, seizure-related disorders, and neurological disorders. It is targeting disorders such as intellectual disability, severe speech impairment, problems with movement and balance, sleep disorders and anxiety to transform the patients life. Additional info from NASDAQ: |
📋 Jeffrey A. Rona (Affiliated Stockholder) plans to sell 150K shares of OVID THERAPEUTICS INC. (at $2.80 each, total $420K) Filed: Aug 14, 2026 | ID: 000005
Read moreNew Form SCHEDULE 13G/A - Ovid Therapeutics Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-097342 <b>Size:</b> 13 KB
Read moreNew Form SCHEDULE 13G/A - Ovid Therapeutics Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001231919-26-000926 <b>Size:</b> 15 KB
Read moreNew Form SCHEDULE 13G/A - Ovid Therapeutics Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001580642-26-005303 <b>Size:</b> 12 KB
Read moreNew Form SCHEDULE 13G/A - Ovid Therapeutics Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003432 <b>Size:</b> 15 KB
Read moreNew Form SCHEDULE 13G/A - Ovid Therapeutics Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001011438-26-000510 <b>Size:</b> 10 KB
Read more(30% Negative) OVID THERAPEUTICS INC. (OVID) Reports Q3 2026 Financial Results
Read moreOvid Therapeutics Inc. - Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Read moreOvid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Read moreCarter Charles Ross 🟢 acquired 50.0K shares of Ovid Therapeutics Inc. (OVID) Transaction Date: Jul 06, 2026 | Filing ID: 000004
Read more